Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.
about
Multimodal management of muscle-invasive bladder cancerHuman epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer.'Image and treat': an individualized approach to urological tumorsHuman epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parametersA transcriptome signature of endothelial lymphatic cells coexists with the chronic oxidative stress signature in radiation-induced post-radiotherapy breast angiosarcomas.Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value.Expression of NRG1 and its receptors in human bladder cancer.Urothelial carcinomas: a focus on human epidermal receptors signalingHybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.HER2 in solid tumors: more than 10 years under the microscope; where are we now?Novel molecular targets for urothelial carcinomaSomatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial TumorsMorphological and molecular characteristics of HER2 amplified urothelial bladder cancerHER2 as a target in invasive urothelial carcinoma.Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniquesEvidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer.Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.Contemporary management of muscle-invasive bladder cancerAdvanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder.Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Novel strategies for treating relapsed/refractory urothelial carcinoma.Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial CarcinomaPrevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma.HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patientsStatus of Her2 over expression in muscle invasive urothelial bladder carcinoma: Report of 21 cases.Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.The human epidermal growth factor receptor 2 (HER2).Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.Biomolecular predictors of urothelial cancer behavior and treatment outcomes.Molecular targets on the horizon for kidney and urothelial cancer.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.New treatments for bladder cancer: when will we make progress?Predictive markers in bladder cancer: do we have molecular markers ready for clinical use?
P2860
Q27011624-E8FA4AFA-F8E7-4E2E-A79B-7B6754DB51D1Q33648897-AC34C9D0-E141-4527-89C3-C70CDF436880Q33792596-80D74948-ED04-4927-B936-F81DCD9468FDQ33802832-AE4A3AF9-0DE4-47E8-80D6-9376859DD33BQ34270766-9768EF4D-B446-433A-AA04-07AF444C1104Q34674350-08754356-89C3-43A0-9079-A83586B39E03Q34745805-D756E528-A4AA-41A8-B58B-23A2B088BEF7Q35172558-C05A0C81-1590-4237-B753-328EC6AAFBC4Q35195417-A5FA0BBB-6C8D-43E3-B662-4E2C55B59AA9Q35211263-64D61B38-473D-4909-9A9D-D9E2EC382ED3Q35527068-40B34DE6-231C-4645-80F9-64219DF18016Q35651546-79536D78-48FF-4028-B8A0-443931166B9EQ35698114-8A989D51-B892-4D3C-8EB3-C79C1F4074BAQ35755382-D91718AE-39DE-41C5-AE69-69C09F079CFBQ35905097-96BC4D2D-6B9E-4391-852C-D75AA5C80B3FQ36027204-BC93DB67-45E3-440E-AEDD-D6796EEC3D89Q36107543-0CEA2E75-D015-40A0-8002-130BFF3050C3Q36121689-D5C16A11-D3D6-4CC7-81D0-B549B4C774BBQ36185012-0FAC0ED2-7AFF-4357-B47F-0BCFAE1B7634Q36342637-AA161A5B-1A85-4083-AAD9-A314E8C7A28DQ36389716-742E160E-0C39-42BF-AE80-9240A1DEA06EQ36589753-9F168B37-F151-479A-863A-DDB1BF19C18FQ36724623-BE2336EC-D58B-4643-83A4-8797CB4BDD82Q36785721-6EAE1B94-F712-4631-8919-357BB76456E4Q36995686-C7F187EC-E146-4843-8073-E142FED14A5BQ37110135-CDD5BC6A-5E6C-4B4F-9A11-68613F0EA8B7Q37122307-F32EE7EE-9810-4B71-9058-429278C55140Q37438701-758E4B1B-6EE2-42B9-89B7-8FC609D64C25Q37587395-6EDE55FC-2A71-4CE6-AC34-456AF0E6FBE1Q37658136-9D24BE9A-56D5-42C0-A310-2B57E947281BQ37866150-D04A4BD7-FE38-48E9-BB85-A4F4F5D36D16Q37899910-CD660594-A3B6-481A-B732-8C4728D3F57EQ37932507-A07FF80D-660B-4A6E-A635-F2A603191669Q37941807-4DAB8240-5FEB-4D50-B97B-B819335961F2Q37987066-C60AC9C0-9585-4592-B864-55AE0EA12B80Q38132039-31B2A753-3706-44AE-949D-5155076CB2CDQ38152999-002C994F-4AA1-43EE-AEC5-4845105CEDC8Q38155201-BEFCC684-51D7-4EAF-A914-F3541C822986Q38177753-E3065CEB-B4CB-4A1B-A64B-E616C9FACF40Q38230912-4F81E280-99AB-4776-BA33-AE74BF123DF5
P2860
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Assessing HER2 gene amplificat ...... ogy: results in 1005 patients.
@ast
Assessing HER2 gene amplificat ...... ogy: results in 1005 patients.
@en
type
label
Assessing HER2 gene amplificat ...... ogy: results in 1005 patients.
@ast
Assessing HER2 gene amplificat ...... ogy: results in 1005 patients.
@en
prefLabel
Assessing HER2 gene amplificat ...... ogy: results in 1005 patients.
@ast
Assessing HER2 gene amplificat ...... ogy: results in 1005 patients.
@en
P2093
P2860
P356
P1433
P1476
Assessing HER2 gene amplificat ...... logy: results in 1005 patients
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDP488
P577
2009-11-04T00:00:00Z